Canada markets closed

Cumberland Pharmaceuticals Inc. (CPIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4900+0.0500 (+3.47%)
At close: 04:00PM EDT
1.4500 -0.04 (-2.68%)
After hours: 05:52PM EDT

Cumberland Pharmaceuticals Inc.

1600 West End Avenue
Suite 1300
Nashville, TN 37203
United States
615 255 0068
https://www.cumberlandpharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees91

Key Executives

NameTitlePayExercisedYear Born
Mr. A. J. Kazimi MBAFounder, Chairman, President & CEO952.53kN/A1958
Mr. John Michael HammVP & CFO258.38kN/A1956
Mr. James Lowrance HermanExecutive VP of National Accounts & Chief Compliance Officer372.27kN/A1955
Mr. Chris T. BittermanVice President of Sales & Marketing290.87kN/A1965
Mr. Todd M. AnthonyVice President of Organizational Development304.94kN/A1961
Ms. Jean W. MarstillerSenior VP of Administrative Services & Corporate Secretary282.17k38.53k1950
Mr. Adam S. MostafaManaging DirectorN/AN/A1980
Ms. Erin Smith GullSenior Corporate Relations AssociateN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Corporate Governance

Cumberland Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.